Suntory Limited

Mitsui Petrochemical Industries, Ltd.

Bizen Chemical Co., Ltd.

Takafumi Ishihara

Toshio Tatsuoka

Akira Mizuno

Hidetsura Cho

Mikiko Hamaguchi

Noriaki Kihara

Ikuo Tomino

Fumio Satoh

Mikiko Miya

Kengo Akimoto

Norio Inomata

Kenichi Higashiyama

Kunihiro Sumoto

Seiji Miyano

Hiroaki Tan

Kayoko Nomura

Mitsuyuki Takesue

Fumio Sato

Kazuo Aisaka

Motoharu Arai

Keiyu Shima

Yoshiharu Tanaka

Teruyuki Kanada

Kazuyoshi Matsunaga

Toru Kuyama

Takahiko Hada

A method of producing glycogen is provided. The method comprises the step of heat- and pressure-treating a sugar-containing material under acidic conditions. The sugar-containing material is a polysaccharide or an oligosaccharide. Alternatively, the sugar-containing material is a plant material selected from the group consisting of Panax notoginseng, Yun Nan San-chi powder (trademark), Panax ginseng, wheat flour, soybean, soy flour, shiitake, and coffee extract residue. Representatively, the glycogen includes a molecule having a molecular weight of 10,000 or less. The glycogen has a specific rotation of [&#x3b1;]+197&#xb0; and anomeric proton peaks at 5.37 ppm and 4.95 to 5.33 ppm inH NMR spectra.

Process for physicochemically producing glycogen and glycogen obtained thereby

The present invention provides domestic fowl eggs having a high content of arachidonic acid and optionally docosahexaenoic acid obtained by feeding egg-laying domestic fowls &ohgr;6 highly unsaturated fatty acids and optionally &ohgr;3 highly unsaturated fatty acids, their production process, a lipid that originates from them, and a food that contains said lipid.

Domestic fowl eggs having a high content of highly unsaturated fatty acid, their production process and their use

Disclosed herein are pyrroloazepine derivatives having anti-.alpha..sub.1 activity and anti-serotonin activity represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

Pyrroloazepine derivatives

Pyrroloazepine compound

Pyrroloazepine derivative

Disclosed herein are pyrroloazepine derivatives, which are useful as therapeutics for circulatory diseases, represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

A novel N-substituted imidazole or thioimidazole derivative and a pharmacologically acceptable acid addition salt thereof, which have a brain function-improving action, are disclosed. The derivative or salt is used as an effective ingredient of a brain function-improving medicine.

Imidazole derivatives having anti-hypoxia properties

A novel nitrogen-containing compound capable of preventing hardening of blood vessels by controlling formation of peroxide lipids in cell membranes, which is valuable as an anti-arteriosclerotic agent, is disclosed.

Nitrogen-containing compound

2-phenylbenzoxepin derivatives having a hypoglycemic activity, hypotensive activity, and platelet coagulation inhibiting activity, a process for production of the derivatives, and pharmaceutical compositions containing the derivatives.

2-phenylbenzoxepin derivative

A novel pyrrolizidine derivative of the formula, ##STR1## which has potent antiarrhythmic activity and low toxicity is produced. The derivative can be synthesized: by acylating 2,6-xylidine to protect the amino group, nitrating the protected xylidine to introduce a nitro group at 3-position, reducing the nitro group to an amino group, followed by diazotizing and hydrolyzing, and then the resulted 3-hydroxy-2,6-dimethylaniline being condensed with 8-halocarbonylmethylpyrrolizidine; or by nitrating N-(2',6'-dimethyl)phenyl-8-pyrrolizidineacetamide to introduce a nitro group at 3'-position, reducing the nitro group to amino group, diazotizing the amino group and hydrolyzing the diazonium compound.

Pyrrolizidine derivative and pharmaceutical composition thereof

N-substituted 3,4-dihydropyrimidine derivatives of the formula: ##STR1## wherein X.sup.1, X.sup.2 and X.sup.3 are the same or different and are hydrogen, nitro, halogen, cyano, trifluoromethyl, methylthio or lower alkoxy;

2,6-Dimethyl-3N,5-disubstituted-4-(substituted

Growing community of inventors

Takatsuki, Japan

Takafumi Ishihara